FDA approves Lilly's obesity med Zepbound to treat obstructive sleep apnoea
Eli Lilly's Zepbound (tirzepatide) received FDA approval for treating obesity and moderate to severe obstructive sleep apnoea (OSA). The decision was based on SURMOUNT-OSA Phase III trials showing Zepbound reduced breathing disruptions, with 42% and 50% of users achieving remission or mild OSA without and with PAP therapy, respectively. Zepbound also helped patients lose an average of 45 lbs (18% body weight) and 50 lbs (20% body weight) with PAP therapy. The drug, initially approved for obesity, is a GLP-1 receptor agonist also marketed for type 2 diabetes.
Related Clinical Trials
Highlighted Terms
Related News
Eli Lilly's Zepbound (tirzepatide) received FDA approval for treating obesity and moderate to severe obstructive sleep apnoea (OSA). The decision was based on SURMOUNT-OSA Phase III trials showing Zepbound reduced breathing disruptions, with 42% and 50% of users achieving remission or mild OSA without and with PAP therapy, respectively. Zepbound also helped patients lose an average of 45 lbs (18% body weight) and 50 lbs (20% body weight) with PAP therapy. The drug, initially approved for obesity, is a GLP-1 receptor agonist also marketed for type 2 diabetes.